Eleva, a manufacturer of superior biologics, is scaling up its production 
capacity to 2500 l in state-of-the-art single-use reactors. This will produce 
enough factor H to cover all three clinical phases.

Eleva has ordered four more state-of-the-art, 500 l single-use reactors from 
Sartorius Stedim Systems. The scale-up will enable Eleva to enter clinical 
development of factor H, a key component of a pathway of the immune system 
known as alternative complement pathway. 

The complement system enhances (complements) the body's ability to clear 
microbes and damaged cells from an organism. Factor H regulates the activation 
of that immune response and ensures the body's own cells are protected. 
Insufficient regulation of the complement system leads to excessive 
inflammation and potential tissue damage.

Factor H is a complex protein that only Eleva's moss-based platform has thus 
far been able to yield in highest – human-like – quality. Eleva has been able 
to demonstrate a significant reduction in tissue damage and inflammation in 
animal models when its recombinant factor H was supplemented.

Ralf Smit, CBO: "Not only can we now produce sufficient amounts of our own drug 
candidates for all clinical stages, but we are also in a position to offer 
production capacity at industrial scale."

While Eleva will be pursuing the development of its own pipeline products, it 
is also open for joint projects with other pharmaceutical companies. 

About Eleva

Based in Freiburg, Germany, Eleva develops novel biological therapies with its 
pharmaceutical partners. The privately-held company leverages its unique 
moss-based production platform to produce supreme biologics like antibodies, 
replacement enzymes, or fusion toxins. Eleva has successfully developed drug 
candidates into clinical phases.

Press contact 
eleva GmbH
Fabienne Zeitter 
pr@elevabiologics.com
Phone: +49 761 470 99 0
www.elevabiologics.com


Source: eleva GmbH